Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy

Bombardieri, Emilio; Grippa, F.; Cataldo, Ignazio; Chiti, Arturo; Seregni, Ettore; Soresi, E.; Boffi, Roberto; Invernizzi, Giovanni; Buraggi, G.L.

doi:10.1016/0959-8049(94)00467-j

Cited by 35 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, only in 24% of patients did the Octreoscan scintigraphy identify all tumour lesions correctly. Our data are in line with several other reports using Octreoscan [20][21][22][23][24][25][26]. Most of these investigations describe better sensitivity for the detection of primary tumours (78-100%) and mediastinal lymph nodes (69-94%) than distant metastases (26-45%).…”

Section: Discussionsupporting

confidence: 95%

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial

et al. 2004

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 95%

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial

et al. 2004

View full text Add to dashboard Cite

“…Clinical study Semprebene [39] SCLC (19/22) Octreoscan n.a. Clinical study Bombardieri [2] SCLC (20/2 1) Octreoscan n.a. Clinical study Berenger [11] SCLC (19/19) a Octreoscan n.a.…”

Section: Discussionmentioning

confidence: 99%

“…several data have appeared regarding sst expression in endocrine neoplasms in lung tumors. In the same tumors, sst binding sites were reported by means of in vivo studies based on octreotide scintigraphy [1,2,22,26,47]. The tissue localization of sst in lung tumors was analyzed by means of autoradiography [29,32], in situ hybridization [10,25,31] and immunohistochemistry [9,11,25,32,34].…”

Section: Introductionmentioning

confidence: 99%

Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours

et al. 2001

View full text Add to dashboard Cite

The increasingly popular use of somatostatin analogs in clinical practice for both diagnostic and therapeutic purposes prompted extensive investigations on somatostatin receptor (sst) expression in human tumors by autoradiography, nucleic acid analysis and, recently, immunohistochemistry (IHC). The currently employed radiotracer for scintigraphy (Octreoscan) is octreotide, a somatostatin analog having a high affinity for sst types 2, 3, and 5. In this study on 25 patients, we compared sst 2, 3, and 5 expression in surgical and biopsy specimens of lung tumors, as revealed by immunohistochemical and reverse transcriptase polymerase chain reaction (RT-PCR), with the octreoscan outcome (which was positive in 20/25 cases). By IHC, the tumors mainly expressed sst2 (17/25, 68%) at the cell membrane level, while sst 3 and 5 were detected in a fraction of cases (24% and 20%, respectively). Comparing RT-PCR and IHC data, a correlation was found in 83.3% of cases, while octreoscan findings and sst expression were correlated in 22/25 cases (88%). In addition, cytological and biopsy specimens expressed the same sst type found in the corresponding surgical sample, thus indicating that a cell membrane sst immunoreactivity in a biopsy reliably predicts the tumor-receptor profile before its resection. Finally, sst expression was not restricted to neuroendocrine lung tumors, but was also a feature of some non-neuroendocrine carcinomas, although to a lesser extent. The occasional expression of sst subtypes in intratumoral lymphocytes, endothelia and necrotic areas is an additional feature to be considered in the interpretation of Octreoscan findings, since the in vivo procedure does not allow to define the sst cellular distribution. IHC can therefore be usefully coupled to radionuclear investigations to better characterize the sst cellular location and subtype in lung tumors.

show abstract

“…Overall sensitivity in detecting the metastases was 54%, being higher for regional metastases (60%) and lower for distant metastases (45%). In an article published by Bombardieri et al [69] the primary tumours were detected with a sensitivity of 95% and the metastases with a sensitivity of 80%. For the detection of the primary, Krenning et al [13], O'Byrne et al [70] and Kwekkeboom et al [71] reported a sensitivity of 100%; Kirsch et al [72] reported a sensitivity of 96% and Maini et al [73] a sensitivity of 87%.…”

Section: Small Cell Lung Cancersmentioning

confidence: 99%

Somatostatin receptor SPECT

Pepe

Moncayo

Bombardieri³

et al. 2012

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Somatostatin is a peptide with a broad distribution in the nervous system and acts as a neurotransmitter in several organs, having a wide range of mainly inhibiting effects, such as the suppression of growth hormone release, as well as the inhibition of pancreatic and gastrointestinal hormone release. Five somatostatin receptor subtypes have been cloned and demonstrated to have an emphasized expression in all human tumours. In particular, type 2 receptors were identified as the most frequently represented on the surface of neuroendocrine tumour cells, providing the molecular basis for many clinical applications of somatostatin analogues. Towards the end of the 1980s, the in vivo demonstration of somatostatin receptors on the surface of some tumours raised interest in receptor imaging, and indeed the peptide receptor overexpression on tumour cells, as compared to normal tissues, constitutes the basis for molecular imaging of these tumours. This review intends to illustrate the development of single photon emission radiopharmaceuticals for the study of somatostatin receptors and their application in diagnostic imaging.

show abstract

Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy

Cited by 35 publications

References 20 publications

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial

Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours

Somatostatin receptor SPECT

Contact Info

Product

Resources

About